Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 138 clinical trials
featured
HERV-E TCR Transduced Autologous T Cells in People With Metastatic Clear Cell Renal Cell Carcinoma

of agents such as VEGF, mTOR inhibitors and immunotherapy (high-dose (HD) IL-2 or immune-checkpoint inhibitors). Long-term survival can be achieved with high-doses IL-2 or immune-checkpoint inhibitors

renal cell cancer
metastatic cancer
clear cell carcinoma
primary cancer
carcinoma
  • 144 views
  • 22 Dec, 2020
  • 1 location
A New Treatment for Primary Smear-positive Pulmonary Tuberculosis With Interleukin-2

The purpose of the study is to compare the efficacy and safety of standard chemotherapy regimen 2HRZE/4HR plus IL-2 and standard regimen 2HRZE/4HR for newly diagnosed smear positive pulmonary

  • 0 views
  • 04 Mar, 2021
  • 16 locations
Lentivirus Transduced Acute Myeloid Leukaemia Blasts Expressing B7.1 (CD80) and IL-2

The purpose of this study is to assess the safety and tolerability of an 'AML Cell Vaccine' in patients with poor prognosis acute myeloid leukaemia (AML).

remission
graft versus host disease
  • 17 views
  • 07 Nov, 2020
  • 1 location
Adoptive Tumor-infiltrating Lymphocyte Transfer With Nivolumab for Melanoma

after non-myeloablative chemotherapy with cyclophosphamide and fludarabine. TIL transfer will be combined with low dose Interleukin (IL)-2 and nivolumab anti-PD-1 treatment. The study uses a

liver metastasis
measurable disease
cyclophosphamide
platelet count
metastasis
  • 0 views
  • 25 Jan, 2021
  • 1 location
Adoptive Cell Therapy Following a Non-myeloablative Lymphodepleting Induction Regimen in Metastatic Melanoma Patients

Adoptive cell therapy (ACT) with tumor-infiltrating lymphocytes (TILs) in combination with lymphodepletion and high-dose interleukin 2 (IL-2) has demonstrated reproducible objective response

  • 10 views
  • 22 Jan, 2021
  • 1 location
Immunochemotherapy for Metastatic Renal Cell Carcinoma

Immunochemotherapy consisting of IL-2, INF-A, and VBL and 5FU is regarded as the treatment of choice in metastatic renal cell carcinoma. During the period 1996-2000, we evaluated the

  • 25 views
  • 07 Nov, 2020
  • 1 location
Saltikva for Metastatic Pancreatic Cancer

Objectives: Assess the efficacy of multiple dose oral administration of Saltikva, an attenuated strain of Salmonella Typhimurium expressing IL-2, in patients with metastatic pancreatic cancer on

  • 0 views
  • 26 Jan, 2021
  • 1 location
INFUSION OF ALLOREACTIVE NATURAL KILLER (NK) CELLS AS CONSOLIDATION STRATEGY FOR ACUTE MYELOID LEUKEMIA PATIENTS

infused intravenously with a single dose of cryopreserved NK cells (day 0), which will be followed by subcutaneous administration of Interleuki (IL)-2 (10 x 106 IU/day, 3 times weekly) for 2 weeks (6

fludarabine
leukapheresis
cyclophosphamide
cell transplantation
immunosuppressants
  • 0 views
  • 03 Feb, 2021
  • 1 location
Activity and Safety of Lenalidomide and Rituximab (LenRtx) as Non-chemotherapy Based Therapy for Patients With Chronic Lymphocytic Leukemia

) triggered by monoclonal antibodies such as rituximab. Lenalidomide augments NK cytotoxicity by increasing CD56dimCD3 subset, in addition to inducing IL-2 in T cells. These results provide the

rituximab
lymphoma
monoclonal protein
lenalidomide
chronic lymphocytic leukemia
  • 18 views
  • 08 Nov, 2020
  • 1 location
Survival TRial Using CytoKines in COVID-19 (STRUCK Trial)

moment) in COVID-19 severe patients, in second study arm. Both approaches (indirect IL-6 and Il-17) are related to modulation of inflammatory immune response. Finally, in third arm, IL-2 low dose. This

  • 0 views
  • 27 Jan, 2021
  • 2 locations